Clinical Chemistry, Vol 36, 1803-1807, Copyright © 1990 by American Association for Clinical Chemistry

Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns

JC Jacobs and NM Alexander
Department of Pathology, University of California, San Diego 92103.

After the parenteral administration of iron-dextran (imferon), the increased total iron concentrations in serum can be determined by atomic absorption spectroscopy and by colorimetric methods involving sodium dithionite, which reductively dissociates iron from the dextran complex. We report that constant-potential coulometry detects only about 55-70% of dextran-bound iron before dithionite reduction and variable amounts after reaction with the reducing agent. In addition, we have developed a procedure for determining transferrin-bound iron, total iron-binding capacity (TIBC), total iron, and dextran-bound iron with the Kodak Ektachem colorimetric system. In determining total serum iron, the sample is first mixed with sodium dithionite, which rapidly dissociates all dextran-bound iron, but does not remove iron from either transferrin or hemoglobin. After the mixture is applied to an Ektachem slide, transferrin-bound iron is released at pH 4 and is detected together with the iron previously bound to dextran. TIBC is determined by mixing serum with ferric citrate in moderate excess and filtering through a small alumina (Al2O3) column, which binds excess free iron and iron-dextran; the iron in the column eluate represents the TIBC. Transferrin-bound iron is determined by applying diluted serum without added ferric citrate to an alumina column and measuring the iron in the column eluate. Dextran-bound iron is equivalent to the difference between total and transferrin-bound iron. Using this method, we found that transferrin iron-binding sites are saturated in vitro by excess iron-dextran less efficiently than by ferric citrate.

The following articles in journals at HighWire Press have cited this article:

				D. B. Van Wyck Labile Iron: Manifestations and Clinical Implications J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S107 - S111. [Full Text] [PDF]

				D. Van Wyck, J. Anderson, and K. Johnson Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol. Dial. Transplant., March 1, 2004; 19(3): 561 - 565. [Abstract] [Full Text] [PDF]

				A. BESARAB, S. FRINAK, and J. YEE An Indistinct Balance: The Safety and Efficacy of Parenteral IronTherapy J. Am. Soc. Nephrol., September 1, 1999; 10(9): 2029 - 2043. [Full Text]

				P. A. Seligman and R. B. Schleicher Comparison of Methods Used to Measure Serum Iron in the Presence of Iron Gluconate or Iron Dextran Clin. Chem., June 1, 1999; 45(6): 898 - 901. [Full Text] [PDF]

				H. Yamanishi, S. Kimura, S. Iyama, Y. Yamaguchi, and T. Yanagihara Fully automated measurement of total iron-binding capacity in serum Clin. Chem., December 1, 1997; 43(12): 2413 - 2417. [Abstract] [Full Text] [PDF]